Status:
COMPLETED
Screening Evaluation of the Evolution of New Heart Failure (SCREEN-HF)
Lead Sponsor:
Ingrid Hopper
Collaborating Sponsors:
HBA
Conditions:
Heart Failure
Eligibility:
All Genders
60+ years
Brief Summary
The investigators are hoping to identify early heart failure in patients who do not have symptoms as yet and at the same time assess the usefulness of Brain natriuretic peptide (BNP) in doing this.
Detailed Description
Measuring Brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP)and can give us useful information about a persons heart function in patients with symptoms such as shortness of breath. This...
Eligibility Criteria
Inclusion
- Age ≥60 years
- Have been insured with HBA for 12 months or longer (Protocol amended to remove this criteria and allow enrollment of the general public)
- Subjects at high-risk of subsequent development of heart failure; comprising at least one of:
- Prior myocardial infarction (MI) without known left ventricular (LV) dysfunction
- Current active ischemic heart disease
- Prior Cerebrovascular Accident (CVA)
- Known valvular heart disease without known LV dysfunction
- Atrial fibrillation
- Ventricular arrhythmia resulting in syncope or pre-syncope (protocol amended to remove this entry criteria)
- Treated hypertension, of at least 2 years duration
- Treated Diabetes mellitus, of at least 2 years duration
- Estimated Glomerular Filtration Rate (eGFR) \<50ml/min
Exclusion
- Known systolic or diastolic heart failure
- Symptoms suggestive of current heart failure. (protocol amended to remove this criteria)
- LV systolic or diastolic dysfunction on echocardiography or other objective imaging modality.
- Medications for treatment of heart failure such as ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers or aldosterone antagonists. Use of such medications for approved indications such as hypertension, post-MI management (without known LV dysfunction) or for diabetic nephropathy is permitted. (protocol amended to remove this criteria)
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
3500 Patients enrolled
Trial Details
Trial ID
NCT00400257
Start Date
May 1 2007
End Date
December 1 2015
Last Update
June 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred Hospital
Melbourne, Victoria, Australia, 3004